Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
09
2021
accepted:
05
11
2021
entrez:
18
11
2021
pubmed:
19
11
2021
medline:
1
12
2021
Statut:
epublish
Résumé
SARS-CoV-2 viral attachment and entry into host cells is mediated by a direct interaction between viral spike glycoproteins and membrane bound angiotensin-converting enzyme 2 (ACE2). The receptor binding motif (RBM), located within the S1 subunit of the spike protein, incorporates the majority of known ACE2 contact residues responsible for high affinity binding and associated virulence. Observation of existing crystal structures of the SARS-CoV-2 receptor binding domain (SRBD)-ACE2 interface, combined with peptide array screening, allowed us to define a series of linear native RBM-derived peptides that were selected as potential antiviral decoy sequences with the aim of directly binding ACE2 and attenuating viral cell entry. RBM1 (16mer): S443KVGGNYNYLYRLFRK458, RBM2A (25mer): E484GFNCYFPLQSYGFQPTNGVGYQPY508, RBM2B (20mer): F456NCYFPLQSYGFQPTNGVGY505 and RBM2A-Sc (25mer): NYGLQGSPFGYQETPYPFCNFVQYG. Data from fluorescence polarisation experiments suggested direct binding between RBM peptides and ACE2, with binding affinities ranging from the high nM to low μM range (Kd = 0.207-1.206 μM). However, the RBM peptides demonstrated only modest effects in preventing SRBD internalisation and showed no antiviral activity in a spike protein trimer neutralisation assay. The RBM peptides also failed to suppress S1-protein mediated inflammation in an endogenously expressing ACE2 human cell line. We conclude that linear native RBM-derived peptides are unable to outcompete viral spike protein for binding to ACE2 and therefore represent a suboptimal approach to inhibiting SARS-CoV-2 viral cell entry. These findings reinforce the notion that larger biologics (such as soluble ACE2, 'miniproteins', nanobodies and antibodies) are likely better suited as SARS-CoV-2 cell-entry inhibitors than short-sequence linear peptides.
Identifiants
pubmed: 34793553
doi: 10.1371/journal.pone.0260283
pii: PONE-D-21-28336
pmc: PMC8601423
doi:
Substances chimiques
Antiviral Agents
0
Peptides
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0260283Subventions
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/7
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Curr Top Med Chem. 2007;7(1):33-62
pubmed: 17266595
Biochim Biophys Acta. 2015 Feb;1848(2):688-94
pubmed: 25434927
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
BMC Cancer. 2019 Mar 25;19(1):266
pubmed: 30909892
Oncogene. 2020 Feb;39(6):1167-1184
pubmed: 31636382
Pept Sci (Hoboken). 2021 Jan 08;:e24217
pubmed: 33615115
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Science. 2020 Oct 23;370(6515):426-431
pubmed: 32907861
J Mol Cell Cardiol. 2011 May;50(5):872-83
pubmed: 21334344
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):13-20
pubmed: 8552589
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Anal Biochem. 2015 Nov 15;489:1-8
pubmed: 26278171
Mol Pharmacol. 2016 May;89(5):505-20
pubmed: 26873857
Drug Discov Today. 2018 Feb;23(2):272-285
pubmed: 29097277
Commun Biol. 2021 Feb 12;4(1):197
pubmed: 33580154
Signal Transduct Target Ther. 2020 Sep 23;5(1):213
pubmed: 32968059
Virol J. 2021 Jul 23;18(1):154
pubmed: 34301275
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell Mol Immunol. 2020 Jun;17(6):621-630
pubmed: 32415260
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1533-42
pubmed: 23509299
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Vis Exp. 2014 Nov 18;(93):e52097
pubmed: 25490271
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
J Cell Physiol. 2021 Oct;236(10):7045-7057
pubmed: 33755190
FEBS Open Bio. 2014 Oct 28;4:923-7
pubmed: 25426411
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
mBio. 2020 Dec 11;11(6):
pubmed: 33310780
Antiviral Res. 2012 Jun;94(3):288-96
pubmed: 22265858
Mol Psychiatry. 2018 May;23(5):1278-1286
pubmed: 28727686
Cell Signal. 2017 Dec;40:62-72
pubmed: 28851628
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677
Proteins. 2021 May;89(5):569-576
pubmed: 33423311
Nature. 2020 May;581(7807):215-220
pubmed: 32225176